DAILYZ HEALTH NEWS

The New England Journal of Medicine retracted a 2019 paper on Amgen’s Tavneos trial after FDA found data manipulation and proposed withdrawing approval.

Health

June 25, 2026 Evan Vega

FDA Expands Pfizer’s Ibrance as Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer

The FDA approved Pfizer’s Ibrance as maintenance therapy for HR-positive, HER2-positive metastatic breast cancer in combination with trastuzumab and endocrine therapy.

Health

June 25, 2026 Evan Vega

HHS Proposes Clinical Trial Reform to Restrict Chinese Biotech Sector Participation

The U.S. HHS proposed clinical trial reforms to limit Chinese biotech participation and boost domestic drug development.

Health

June 16, 2026 Evan Vega

Global obesity surge driving premature heart disease with peak rates now in people in their early 50s and fastest growth in South Asia, major ENDO 2026 study reports

A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.

$Semaglutide lowers fracture risk$

Health

June 16, 2026 Evan Vega

GLP-1 diabetes and obesity drugs like semaglutide tied to 15% lower fracture risk and potential bone health benefits versus other weight-loss medications

GLP-1 drugs like semaglutide linked to 15% lower fracture risk and greater weight loss in type 2 diabetes patients versus other obesity medications.

Health

June 16, 2026 Evan Vega

Long daytime naps over 30 minutes linked to higher risk of fatty liver disease in people with type 2 diabetes, new ENDO 2026 data suggest

A study at ENDO 2026 found that type 2 diabetes patients who nap over 30 minutes have a higher risk of fatty liver disease.

Health

June 15, 2026 Evan Vega

Bangladesh measles outbreak death toll surpasses 650 children as WHO and UNICEF rush emergency vaccination support to curb regional spread

Bangladesh’s measles outbreak has killed over 650 children, prompting WHO and UNICEF to launch emergency vaccinations for young children.

Health

June 14, 2026 Evan Vega

FDA clears first gene-edited cell therapy for severe sickle cell disease, paving way for wider use of CRISPR-based treatments in US hospitals

The FDA approved CASGEVY™, the first CRISPR gene-edited cell therapy, for severe sickle cell disease patients 12 and older with recurrent crises.

Global Drug-Resistant Tuberculosis Emergency

Health

June 5, 2026 Evan Vega

WHO Issues Global Health Emergency Over Rapidly Spreading Drug-Resistant Tuberculosis Strain as Cases Detected in U.S. Travelers

The WHO has not declared a global health emergency over the drug-resistant tuberculosis strain linked to U.S. travelers as of mid-2025.

Health

June 4, 2026 Evan Vega

Biden administration unveils new plan to cap insulin out-of-pocket costs at $35 for all insured Americans, expanding earlier Medicare-only protections

The Biden administration announced a plan to cap insulin out-of-pocket costs at $35 monthly for all insured Americans, expanding beyond Medicare.

DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

Medical Journal Retracts Paper on Amgen’s Tavneos Drug Trial After FDA Findings

FDA Expands Pfizer’s Ibrance as Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer

HHS Proposes Clinical Trial Reform to Restrict Chinese Biotech Sector Participation

Global obesity surge driving premature heart disease with peak rates now in people in their early 50s and fastest growth in South Asia, major ENDO 2026 study reports

GLP-1 diabetes and obesity drugs like semaglutide tied to 15% lower fracture risk and potential bone health benefits versus other weight-loss medications

Long daytime naps over 30 minutes linked to higher risk of fatty liver disease in people with type 2 diabetes, new ENDO 2026 data suggest

Bangladesh measles outbreak death toll surpasses 650 children as WHO and UNICEF rush emergency vaccination support to curb regional spread

FDA clears first gene-edited cell therapy for severe sickle cell disease, paving way for wider use of CRISPR-based treatments in US hospitals

WHO Issues Global Health Emergency Over Rapidly Spreading Drug-Resistant Tuberculosis Strain as Cases Detected in U.S. Travelers

Biden administration unveils new plan to cap insulin out-of-pocket costs at $35 for all insured Americans, expanding earlier Medicare-only protections